RxDoctor Payments Data

Mark Spatz, PA

Physician Assistant · Columbus, GANPI 1083803068

Payments from drug & device makers

$11,551in general payments, 2019–2025

Across 407 payments — averaging $28.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Regeneron Healthcare Solutions, Inc.$2K
  • Amgen$1K
  • Sanofi$829
  • LEO Pharma Inc.$528
  • Dermavant Sciences, Inc.$507
  • plus $4K from 19 others

What the payments were for

  • Speaking & faculty fees$220%
  • Food & beverage$11,42899%
  • Education$1011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,551 in reported general payments places this provider in the 95th percentile of 3,581 physician assistant providers in Georgia.

See all physician assistant providers in Georgia

Medicare billing

Part B allowed, 2024
$270,466
Medicare patients
1,503
Services billed
7,011

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa14$281,474
Humira(Cf) PenAdalimumab28$225,112
OtezlaApremilast32$152,105
Dupixent PenDupilumab37$137,862
Dupixent SyringeDupilumab27$102,055
Cosentyx Sensoready (2 Pens)Secukinumab13$94,220
HumiraAdalimumab11$88,408
VtamaTapinarof13$18,185
Clobetasol Propionate91$4,316
Fluorouracil41$3,371
Clobetasol EmollientClobetasol Propionate/Emoll54$3,298
Isotretinoin13$3,031
Ketoconazole129$2,280
Doxycycline Hyclate127$2,173
Triamcinolone Acetonide178$2,170

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$1,221$152,10532 claims
AbbVieHumira$3,208$88,40811 claims
Dermavant Sciences, Inc.Vtama$507$18,18513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,581 physician assistant providers in Georgia.

Other physician assistant in Columbus

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →